Teva Branded Pharm patents expiration
1. Austedo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(7 years from now) | |
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(8 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11648244 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
|
US11357772 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11446291 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11648244 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11564917 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(14 years from now) | |
|
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| M (M) | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
Dosage: TABLET;ORAL
AUSTEDO family patents
2. Loseasonique patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(3 months ago) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(3 months ago) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(5 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 24 October, 2008
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
LOSEASONIQUE family patents
3. Proair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7540282 | TEVA BRANDED PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(4 months ago) | |
| US9463288 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 7 months from now) | |
| US10765820 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 7 months from now) | |
| US8651103 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
Mar, 2028
(4 years from now) | |
| US9731087 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US10124131 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US9216260 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(7 years from now) | |
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
| US8978966 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
| US9782551 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US9782550 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(11 years from now) | |
| US10918816 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(12 years from now) | |
| US10569034 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(12 years from now) | |
| US11351317 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Feb, 2038
(14 years from now) | |
| US11357935 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Sep, 2038
(14 years from now) | |
| US11000653 | TEVA BRANDED PHARM | Inhaler |
Dec, 2038
(15 years from now) | |
| US11344685 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Sep, 2039
(16 years from now) | |
| US11439777 | TEVA BRANDED PHARM | Drug delivery device with electronics |
May, 2040
(16 years from now) | |
| US11464923 | TEVA BRANDED PHARM | Inhaler system |
Jun, 2040
(16 years from now) | |
| US11173259 | TEVA BRANDED PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(16 years from now) | |
| US11266796 | TEVA BRANDED PHARM | Inhalation device with integrated electronics |
Feb, 2041
(17 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR DIGIHALER family patents
4. Proair Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7105152 | TEVA BRANDED PHARM | Suspension aerosol formulations |
Sep, 2023
(16 days ago) | |
| US8132712 | TEVA BRANDED PHARM | Metered-dose inhaler |
Sep, 2028
(4 years from now) | |
| US10695512 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10022509 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US9808587 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10086156 | TEVA BRANDED PHARM | Dose counter for inhaler and method for counting doses |
May, 2031
(7 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US9463289 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US11395889 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
PROAIR HFA family patents
5. Qnasl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7780038 | TEVA BRANDED PHARM | Dispensing apparatus with dosage counter |
Jan, 2027
(3 years from now) | |
| US10188811 | TEVA BRANDED PHARM | Nasal spray device |
Oct, 2031
(8 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 23 March, 2012
Treatment: NA
Dosage: AEROSOL, METERED;NASAL
QNASL family patents
6. Quartette patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450299 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Oct, 2025
(2 years from now) | |
| US8415332 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Mar, 2029
(5 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 28 March, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
QUARTETTE family patents
7. Qvar 40 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11395889 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10086156 | TEVA BRANDED PHARM | Dose counter for inhaler and method for counting doses |
May, 2031
(7 years from now) | |
| US9808587 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10695512 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US10022509 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US9463289 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR 40 family patents
8. Seasonique patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(3 months ago) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(3 months ago) | |
| US7320969 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jan, 2024
(4 months from now) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(5 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 25 May, 2006
Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
SEASONIQUE family patents
9. Vantrela Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216176 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US9572803 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US8445018 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Jul, 2029
(5 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 17 January, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
VANTRELA ER family patents
10. Zecuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6745071 | TEVA BRANDED PHARM | Iontophoretic drug delivery system |
Feb, 2023
(7 months ago) | |
| US8155737 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(3 years from now) | |
| US8470853 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(3 years from now) | |
| US7973058 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(3 years from now) | |
| US9427578 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(3 years from now) | |
| US8597272 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(3 years from now) | |
| US9272137 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Sep, 2027
(3 years from now) | |
| US8366600 | TEVA BRANDED PHARM | Polyamine enhanced formulations for triptan compound iontophoresis |
Apr, 2029
(5 years from now) | |
| US8983594 | TEVA BRANDED PHARM | Electronic control of drug delivery system |
Nov, 2030
(7 years from now) | |
| US9327114 | TEVA BRANDED PHARM | User-activated self-contained co-packaged iontophoretic drug delivery system |
Oct, 2032
(9 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with ...
Dosage: SYSTEM;IONTOPHORESIS
ZECUITY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic